Treatment of Dermatologic Disorders

Total Page：16

File Type：pdf, Size：1020Kb

CHAPTER 32 Treatment of Dermatologic Disorders PART 11 LEARNING OBJECTIVES PRONUNCIatIONS After completing this chapter, you should be able to Astringent (uh-STRIN-jent) 1. Define the most common dermatologic disorders Cellulitis (cel-yoo-LIE-tis) Comedone (KOH-meh-dohn) 2. Explain the disease process (pathophysiology) of each dermatologic disorder Dermatitis (der-muh-TIE-tis) 3. Describe nonpharmacologic treatment options for dermatologic disorders Dermatophytosis (dur-mat-oh-FYE- 4. State the brand and generic names of the most widely used medications indicated toh-sis) for dermatologic disorders, along with their routes of administration, dosage forms, Emollient (ee-MOL-yunt) and available doses Folliculitis (foh-lik-yoo-LIE-tis) Impetigo (im-peh-TIE-goh) 5. Explain the mechanism of action and common adverse effects of prescription and Onychomycosis (ON-i-ko-mi-KO-sis) nonprescription agents for the treatment of dermatologic disorders Psoriasis (sor-IE-uh-sis) 6. Recognize commonly used treatment regimens for each dermatologic disorder Teratogen (the-RAT-oh-jen) Tinea (TIN-ee-ah) Urushiol (yoo-ROO-shee-ol) Workbook for Understanding Pharmacology for Pharmacy Technicians 122 Matching I Matching II Match each brand name acne product to its generic name. Match each brand name topical corticosteroid to its generic For additional study, label the ones that can be adminis- name. For additional study, list the dosage forms (cream, tered orally. gel, etc.) available. Generic Generic Brand Names Names Oral Administration Brand Names Names Dosage Form 1. Aczone 1. Aclovate 2. Akne-Mycin 2. ApexiCon 3. Amnesteem 3. Clobex 4. Avage 4. Cloderm 5. Avita 5. Cordran 6. Benzac AC 6. Cormax 7. BenzaShave 7. Cutivate 8. Benziq 8. DesOwen 9. Brevoxyl 9. Elocon 10. Claravis 10. Halog 11. ClindaMax 11. Kenalog 12. Desquam-X 12. Locoid 13. Differin 13. Luxiq 14. Epiduo 14. Olux 15. Ery-Tab 15. Synalar 16. Evoclin 16. Temovate 17. Pacnex 17. Topicort 18. PanOxyl 18. Ultravate 19. Renova 19. Vanos 20. Retin-A 20. Westcort 21. Sotret 22. Tazorac GENERIC NAMES 23. Tretin-X a. alclometasone dipropionate j. flurandrenolide 24. Triaz b. betamethasone valerate k. fluticasone propionate c. clobetasol propionate l. halcinonide 25. Vibramycin d. clocortolone pivalate m. halobetasol propionate GENERIC NAMES e. desonide n. hydrocortisone butyrate a. adapalene f. desoximetasone o. hydrocortisone valerate b. benzoyl peroxide g. diflorasone diacetate p. mometasone furoate c. benzoyl peroxide+adapalene h. fluocinolone acetonide q. triamcinolone acetonide d. clindamycin i. fluocinonide e. dapsone f. doxycycline g. erythromycin h. isotretinoin i. tazarotene j. tretinoin.

Copy Link

Recommended publications

(CD-P-PH/PHO) Report Classification/Justifica
COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
[Show full text]
Clinical Policy: Topical Agents: Corticosteroids
Clinical Policy: Topical Agents: Corticosteroids Reference Number: OH.PHAR.PPA.92 Effective Date: 01/01/2020 Revision Log Last Review Date: Line of Business: Medicaid See Important Reminder at the end of this policy for important regulatory and legal information. Description TOPICAL AGENTS: CORTICOSTEROIDS – LOW POTENCY NO PA REQUIRED “PREFERRED” PA REQUIRED “NON- PREFERRED” DESONIDE cream, ointment (generic of Desowen®) ALCLOMETASONE cream, ointment (generic of FLUOCINOLONE ACETONIDE 0.01% cream, solution Aclovate®) (generic of Synalar®) CAPEX® shampoo (fluocinolone acetonide) FLUOCINOLONE body oil, scalp oil (generic of Derma- DESONATE®gel (desonide) Smoothe/ FS®) DESONIDE lotion (generic of Desowen®) HYDROCORTISONE cream, lotion, ointment HYDROCORTISONE ACETATE WITH ALOE gel HYDROCORTISONE WITH UREA cream (generic of Carmol HC®) PANDEL® cream (hydrocortisone probutate) PEDIADERM HC® kit TOPICAL AGENTS: CORTICOSTEROIDS – MEDIUM POTENCY NO PA REQUIRED “PREFERRED” PA REQUIRED “NON--PREFERRED” BETAMETHASONE DIPROPIONATE-CALCIPOTRIENE BETAMETHASONE DIPROPIONATE lotion (generic of Ointment Diprolene®) BETAMETHASONE VALERATE cream, lotion (generic of CLOCORTOLONE PIVALATE (generic of Cloderm®) Valisone®) CORDRAN® tape (flurandrenolide) FLUTICASONE PROPIONATE cream, ointment (generic of DESOXIMETASONE cream, gel, ointment (generic of Cutivate®) Topicort®) MOMETASONE FUROATE cream, ointment, solution FLUOCINOLONE ACETONIDE 0.025% cream, ointment (generic of Elocon®) (generic of Synalar®) PREDNICARBATE cream (generic of Dermatop®) FLUTICASONE
[Show full text]
Steroids Topical
Steroids, Topical Therapeutic Class Review (TCR) September 18, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. September
[Show full text]
A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E
Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2007 A new robust technique for testing of glucocorticosteroids in dogs and horses Terry E. Webster Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Veterinary Toxicology and Pharmacology Commons Recommended Citation Webster, Terry E., "A new robust technique for testing of glucocorticosteroids in dogs and horses" (2007). Retrospective Theses and Dissertations. 15029. https://lib.dr.iastate.edu/rtd/15029 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. A new robust technique for testing of glucocorticosteroids in dogs and horses by Terry E. Webster A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Toxicology Program o f Study Committee: Walter G. Hyde, Major Professor Steve Ensley Thomas Isenhart Iowa State University Ames, Iowa 2007 Copyright © Terry Edward Webster, 2007. All rights reserved UMI Number: 1446027 Copyright 2007 by Webster, Terry E. All rights reserved. UMI Microform 1446027 Copyright 2007 by ProQuest Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. ProQuest Information and Learning Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor, MI 48106-1346 ii DEDICATION I want to dedicate this project to my wife, Jackie, and my children, Shauna, Luke and Jake for their patience and understanding without which this project would not have been possible.
[Show full text]
Pre - PA Allowance Age 18 Years of Age Or Older Quantity 60 Grams Every 90 Days ______
DOXEPIN CREAM 5% (Prudoxin, Zonalon) Pre - PA Allowance Age 18 years of age or older Quantity 60 grams every 90 days _______________________________________________________________ Prior-Approval Requirements Age 18 years of age or older Diagnosis Patient must have the following: Moderate pruritus, due to atopic dermatitis (eczema) or lichen simplex chronicus AND the following: 1. Inadequate response, intolerance or contraindication to ONE medication in EACH of the following categories: a. Topical antihistamine (see Appendix I) b. High potency topical corticosteroid (see Appendix II) 2. Physician agrees to taper patient’s dose to the FDA recommended dose, and after tapered will only use for short-term pruritus relief (up to 8 days) a. Patients using over 60 grams of topical doxepin in 90 days be required to taper to 60 grams topical doxepin within 90 days Prior - Approval Limits Quantity 180 grams for 90 days Duration 3 months ___________________________________________________________________ Prior – Approval Renewal Requirements None (see appendix below) Doxepin 5% cream FEP Clinical Rationale DOXEPIN CREAM 5% (Prudoxin, Zonalon) APPENDIX I Drug Dosage Form Diphenhydramine Cream Phenyltoloxamine Lotion/ Cream Tripelennamine Cream Phendiamine Cream APPENDIX II Relative Potency of Selected Topical Corticosteroid Drug ProductsDosage Form Strength I. Very high potency Augmented betamethasone Ointment, Gel 0.05% dipropionate Clobetasol propionate Cream, Ointment 0.05% Diflorasone diacetate Ointment 0.05% Halobetasol propionate Cream, Ointment 0.05% II. High potency Amcinonide Cream, Lotion, 0.1% Augmented betamethasone Cream,Ointment Lotion 0.05% dipropionate Betamethasone Cream, Ointment 0.05% Betamethasonedipropionate valerate Ointment 0.1% Desoximetasone Cream, Ointment 0.25% Gel 0.05% Diflorasone diacetate Cream, Ointment 0.05% (emollient base) Fluocinonide Cream, Ointment, Gel 0.05% Halcinonide Cream, Ointment 0.1% Triamcinolone acetonide Cream, Ointment 0.5% III.
[Show full text]
Cloderm® Cream (Clocortolone Pivalate 0.1%): a Moisturizing, Hydrating Formulation Enhances Epidermal Barrier Function
CLINICAL INSIGHTS SUPPORTED BY PROMIUS PHARMA 2013, No. 2 Cloderm® Cream (clocortolone pivalate 0.1%): A Moisturizing, Hydrating Formulation Enhances Epidermal Barrier Function Leon Kircik, MD, FAAD It has been shown that application of some topical corti- DermResearch, PLLC, costeroids can increase TEWL and potentially contribute to Physicians Skin Care, PLLC, epidermal barrier dysfunction.6,7 In mice, application of topical Indiana University Medical Center, Indianapolis, IN, corticosteroids induced progressive increases in TEWL and a Mount Sinai Medical Center, New York, NY reduction in intercellular lipids in the SC.7 It is now well known The stratum corneum (SC) is a dynamic structure marked that even short-term use of topical corticosteroids can com- by multiple complex interactions and feedback loops.1-4 Self- promise epidermal barrier function and SC integrity by inhibit- repair of the permeability barrier has been documented; i.e., the ing epidermal lipid synthesis.8 However, certain formulations of SC can quickly adapt and initiate natural physiologic recovery. topical corticosteroids have been shown to improve skin hydra- Dysfunction of the SC is associated with specific disease states, tion and reduce TEWL.9,10 Perhaps the beneficial or detrimental perhaps most notably atopic dermatitis (AD), but also rosacea, effects of a given topical corticosteroid on TEWL have less to do psoriasis, and other inflammatory cutaneous disorders. More with the corticosteroid itself than with the vehicle in which it precisely, researchers and clinicians believe that AD may be is delivered.11 Thus, treatment becomes an act of balancing the driven in part by poor epidermal barrier function, perhaps as negative effects of the corticosteroid molecule itself on epider- a result of impairments in the permeability, immune response, mal barrier versus the positive impact of the vehicle that deliv- and antimicrobial barriers.
[Show full text]
Appendix 6 – Characteristics and Safety Data from the Included Studies
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open Appendix 6 – Characteristics and safety data from the included studies How safe are topical corticosteroids compared to emollient or vehicle? Study ID Study design and Intervention and Participants Cutaneous adverse events Systemic adverse events Unspecified adverse events (Systematic study duration comparator review*) (Quality assessment) Very potent topical corticosteroids Breneman 2003 RCT Intervention: Clobetasol Severity: moderate Local application site skin Unspecified adverse events (1) propionate 0.05% lotion (twice a to severe reactions Incidence comparable between 2 weeks treatment, then day) (n=96) No clinically significant groups. (unpublished) followed up for Age: ≥ 12 years telangiectasia or skin thinning additional 2 weeks Intervention: Clobetasol Treatment-related adverse (Feldman 2005 Sample size: 229 propionate 0.05% emollient events (2) Nankervis (3)) Cochrane risk of bias tool: participants cream (twice a day) (n=100) Clobetasol lotion = 4/96 patients randomisation described, (4.2%); Clobetasol cream = 1/100 allocation concealment Comparator: Vehicle (n=33) patients (1%) unclear, intention-to- Vehicle = 6/33 patients (18.2%) treat unclear. (Difference between groups: p= 0.0006a) Kimball 2008 (4) RCT Intervention: Clobetasol Severity: not Incidence of adverse events or (trial a) propionate emulsion specified in the treatment related adverse Duration not specified in formulation foam 0.05% review events (Frangos 2008 review Clobetasol foam = 8% (5)) Comparator: Vehicle Age: not specified in Risk of bias not assessed Vehicle foam = 10% the review in any of the included (no significant differences systematic reviews.
[Show full text]
(12) Patent Application Publication (10) Pub. No.: US 2008/0045488 A1 RODRGUEZ (43) Pub
US 20080045488A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0045488 A1 RODRGUEZ (43) Pub. Date: Feb. 21, 2008 (54) PREVENTION OF OVARIAN CANCER BY Continuation-in-part of application No. 09/528,963, ADMINISTRATION OF PRODUCTS THAT filed on Mar. 21, 2000, now Pat. No. 6,765,002. INDUCE BIOLOGICAL EFFECTS IN THE Continuation-in-part of application No. 09/672,735, OVARIAN EPTHELIUM filed on Sep. 28, 2000, now Pat. No. 6.511,970. Continuation-in-part of application No. 09/532,340, (75) Inventor: Gustavo C. RODRIGUEZ, Durham, filed on Mar. 21, 2000, now abandoned. NC (US) Publication Classification Correspondence Address: JENNER & BLOCK, LLP (51) Int. Cl. ONE IBM PLAZA A6II 3/56 (2006.01) A 6LX 3/57 (2006.01) CHICAGO, IL 60611 (US) A6IP 35/00 (2006.01) (73) Assignee: New Life Pharmaceuticals Inc., Chi (52) U.S. Cl. ............................................ 514/171; 514/178 cago, IL (US) (57) ABSTRACT The present invention relates to compositions and methods (21) Appl. No.: 11/771,473 for preventing the development of epithelial ovarian cancer (22) Filed: Jun. 29, 2007 by administering compounds in an amount capable of regu lating TGF-B expression in the ovarian epithelium and/or Related U.S. Application Data capable of optimally altering expression of other Surrogate biomarkers identified by microarray technology. HRT and (63) Continuation of application No. 09/798,453, filed on OCP regimens comprising such compositions and methods Mar. 2, 2001. are disclosed. US 2008/0045488 A1 Feb. 21, 2008 PREVENTION OF OVARAN CANCER BY have been thought to increase ovarian cancer risk, whereas ADMINISTRATION OF PRODUCTS THAT INDUCE Some factors that Suppress ovulation have been thought to BIOLOGICAL EFFECTS IN THE OVARAN decrease risk.
[Show full text]
April 1, 2019
BUREAU FOR MEDICAL SERVICES EFFECTIVE WEST VIRGINIA MEDICAID PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA 04/01/2019 This is not an all-inclusive list of available covered drugs and includes only Version 2019.2e managed categories. Refer to cover page for complete list of rules governing this PDL. Prior authorization for a non-preferred agent in any class will be given only if there has been a trial of the preferred brand/generic equivalent or preferred formulation of the active ingredient, at a therapeutic dose, that resulted in a partial response with a documented intolerance. Prior authorization of a non-preferred isomer, pro-drug, or metabolite will be considered with a trial of a preferred parent drug of the same chemical entity, at a therapeutic dose, that resulted in a partial response with documented intolerance or a previous trial and therapy failure, at a therapeutic dose, with a preferred drug of a different chemical entity indicated to treat the submitted diagnosis. (The required trial may be overridden when documented evidence is provided that the use of these preferred agent(s) would be medically contraindicated.) Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC drugs are not covered unless specified. PA criteria for non-preferred agents apply in addition to general Drug Utilization Review policy that is in effect for the entire pharmacy program, including, but not limited to, appropriate dosing, duplication of therapy, etc. The use of pharmaceutical samples will not be considered when evaluating the members’ medical condition or prior prescription history for drugs that require prior authorization.
[Show full text]
LGC Standards Pharmacopoeial Reference Standards 2014
LL CTS INKSP RODUTO A L P ITH W WEBSHO LGC Standards Pharmacopoeial reference standards 2014 FOR STANDARDS WITH CofA SEE OUR CATALOGUE: PHARMACEUTICAL IMPURITIES AND PRIMARY REFERENCE STANDARDS LGC Quality – ISO Guide 34 • GMP/GLP • ISO 9001 • ISO/IEC 17025 • ISO/IEC 17043 Pharmaceutical impurities Code Product CAS No. CS Price Unit Adiphenine Hydrochloride O LGC Standards N O MM1172.00 Adiphenine Hydrochloride 50-42-0 A 250mg HCl Pharmaceutical impurities and Adrenaline Tartrate OH H OH O OH primary reference standardsMM0614.00 2014 N OH Adrenaline Tartrate 51-42-3 A 500mg OH OH O OH OH H MM0614.02 L-Adrenaline 51-43-4 A 500mg OH N OH Imp. C (EP) as Hydrochloride: 1-(3,4-Di- O H OH MM0614.13 hydroxyphenyl)-2-(methylamino)ethanone 62-13-5 A 100mg N HCl Hydrochloride (Adrenalone Hydrochloride) OH (1R)-1-(3,4-Dihydroxyphenyl)-2- OH O S O MM0614.01 methylaminoethanesulphonic Acid H 78995-75-2 A 100mg OH N (Adrenaline -Sulphonate) OH Alanine NH2 MM0566.00 Alanine 56-41-7 A 500mg OH O Imp. A (Pharmeuropa): (2 S)-2-Aminobutanedioic Acid O NH 2 MM0567.00 OH (Aspartic Acid) 56-84-8 A 500mg OH O Albendazole O H MM0382.00 Albendazole N O 54965-21-8 A 500mg N H S N Imp. A (EP): 5-(Propylsulphanyl)-1H- H MM0382.01 N 80983-36-4 A 100mg NH2 benzimidazol-2-amine S N O H Imp. B (EP): Methyl [5-Propylsulphinyl)- N O MM0382.02 N 54029-12-8 A 100mg H 1H-benzimidazol-2-yl]carbamate S N O O H Imp.
[Show full text]
And Their Covered Alternatives for the Premier and Premier Plus Pharmacy Plans 2020 Formulary Exclusions Drug List
Covered and non-covered drugs Drugs not covered — and their covered alternatives for the Premier and Premier Plus pharmacy plans 2020 Formulary Exclusions Drug List 05.03.925.1O (7/20) Formulary Exclusions Drug List effective July 1, 2020 Key Premier and Premier Plus pharmacy plans UPPERCASE Brand-name medicine lowercase italics Generic medicine Category Not covered Covered alternatives Analgesics acetaminophen/caffeine/dihydrocodeine acetaminophen/caffeine/dihydrocodeine cap tab 325-30-16 mg 320.5-30-16mg (generic TREZIX) ALLZITAL (butalbital/acetaminophen) butalbital/acetaminophen 50-325mg bupap butalbital/acetaminophen 50-300mg ANAPROX DS** (naproxen) Generic oral nonsteroidal anti-inflammatory drug FENORTHO* (fenoprofen calcium) FLECTOR PATCH (diclofenac epolamine) INDOCIN SUPP* (indomethacin) INDOCIN SUSP* (indomethacin) ketoprofen 25mg capsules ketoprofen er MOBIC** (meloxicam) NAPRELAN* (naproxen sodium) SPRIX (ketorolac trometh nasal spray) TIVORBEX (indomethacin) VIVLODEX (meloxicam) VOLTAREN** (diclofenac) ZIPSOR (diclofenac potassium) ZORVOLEX (diclofenac) CONZIP* (tramadol ER capsules) tramadol immediate-release or extended-release tablets (generic ULTRAM, ULTRAM ER) DEXPAK 6 DAY** (dexamethasone) dexamethasone tab therapy pack DEXPAK 10 DAY** (dexamethasone) DEXPAK 13** (dexamethasone) TAPERDEX 6 DAY (dexamethasone) LAZANDA (fentanyl citrate nasal spray) fentanyl citrate lozenge (generic ACTIQ) SUBSYS (fentanyl sublingual spray) LIDODERM** (lidocaine) lidocaine patch 5% NALOCET oxycodone-acetaminophen (generic PERCOCET) PERCOCET**
[Show full text]
Adverse Effects of Topical Corticosteroids in Paediatric Eczema: Australasian Consensus Statement
PEER REVIEWED FEATURE Adverse effects of topical corticosteroids in paediatric eczema: Australasian consensus statement Emma Mooney,1 Marius Rademaker,2 Rebecca Dailey,3 Ben S. Daniel,1 Catherine Drummond,4,18 Gayle Fischer,5,13 Rachael Foster,6 Claire Grills,1 Anne Halbert,6 Sarah Hill,2 Emma King,1 Elizabeth Leins,1 Vanessa Morgan,1,7 Roderic J. Phillips,8,9,16 John Relic,10 Michelle Rodrigues,1,11 Laura Scardamaglia,1,3,7,12 Saxon Smith,5,13 John Su,1,3,14,15,16 Orli Wargon17 and David Orchard1 Reproduced from the Australasian Journal of Dermatology 2015; 56(4): 241-251 with the permission of the authors, the Australasian College of Dermatologists and the publisher Wiley Publishing Asia Pty Ltd. © 2015 The Australasian College of Dermatologists. MedicineToday 2015; 16(12): 40-50 ABSTRACT 1 9 Department of Paediatric Dermatology, Department of Vascular Biology, Atopic eczema is a chronic inflammatory disease affecting about Royal Children’s Hospital, 3University of Melbourne, 7Department of 30% of Australian and New Zealand children. Severe eczema Dermatology, Royal Melbourne Hospital, 8Department of Paediatrics, Monash costs over AUD 6000/year per child in direct medical, hospital University, 15Monash University, 11Department of Dermatology, St Vincent’s and treatment costs as well as time off work for care givers and Hospital, 12Department of Dermatology, Western Hospital, 14Department of untold distress for the family unit. In addition, it has a negative Dermatology, Eastern Health, 16Murdoch Children’s Research Institute, impact on a child’s sleep, education, development and self Melbourne, Victoria, 4Department of Dermatology, Canberra Hospital, esteem.
[Show full text]